10 October 2013 | News | By BioSpectrum Bureau
Taiwan-based GNT Biotech gets license from China-based Shenzhen Chipscreen Biosciences for development and commercialization of Chidamide
Singapore: Taiwan-based GNT Biotech has got exclusive license from China-based Shenzhen Chipscreen Biosciences for the development and commercialization of Chidamide in Taiwan.
Chidamide, an oral, selective histone deacetylase (HDAC) inhibitor, is currently being evaluated in phase II trials by Chipscreen Biosciences in peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) and non-small cell lung cancer (NSCLC) patients.
GNTbm will develop and commercialize Chidamide primarily in PTCL, NSCLC and will also retain the rights to develop and commercialize Chidamide in other oncology indications in Taiwan.